Robert D. Arbeit

Tufts Medical Center — United States

Medicine · Health Sciences

47h-index11.1kcitations119works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Mycobacterium research and diagnosis(44), Tuberculosis Research and Epidemiology(43), Antimicrobial Resistance in Staphylococcus(22), Chemokine receptors and signaling(10), Infectious Diseases and Mycology(10)

Publications118 total

Drug susceptibility profiles of Mycobacterium abscessus isolated in the state of São Paulo, 2008–2024
Journal of Medical Microbiology·2025· 1 citedOpen Access
Supplementary Table 2 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Figure 2 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Figure 2 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Data from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Table 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Table 2 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Data from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Figure 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Figure 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Supplementary Table 1 from Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
2023Open Access
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
Cancer Research Communications·2022· 21 citedOpen Access
Serial T-SPOT.TB responses in Tanzanian adolescents: Transient, persistent and irregular conversions
PLoS ONE·2022· 17 citedOpen Access
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Investigational New Drugs·2021· 39 citedOpen Access
Evaluation of the MGIT 960/EpiCenter TB eXiST system for drug susceptibility testing for Mycobacterium abscessus complex
2021· 1 citedOpen Access
DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial
Vaccine·2020· 68 cited
Evaluation of the MGIT 960/EpiCenter TB eXiST system for drug susceptibility testing for Mycobacterium abscessus group
Research Square (Research Square)·2020Open Access
CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial
PLoS ONE·2019· 22 citedOpen Access
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib
Dermatology Online Journal·2018· 5 citedOpen Access
Genetic correlates of clarithromycin susceptibility among isolates of the Mycobacterium abscessus group and the potential clinical applicability of a PCR-based analysis of erm(41)
Journal of Antimicrobial Chemotherapy·2017· 21 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

C. Fordham von Reyn(18), Richard Waddell(9), Joel N. Maslow(7), Thomas W. Barber(6), Susan Tvaroha(6), C. Robert Horsburgh(5), Michael N. Oxman(4), Myron J. Levin(4), Gary R. Johnson(4), Kenneth E. Schmader(4), Heather Williams(4), Carol A. Kauffman(4), Joseph O. Falkinham(4), Richard Brindle(4), Charles F. Gilks(4), Todd A. MacKenzie(4), Mecky Matee(4), Lisa V. Adams(4), Kisali Pallangyo(4), Anna N.A. Tosteson(4)